| 4IH5 | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | 12R | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | De novo fragment design: a medicinal chemistry approach to fragment-based lead generation., Talamas FX, Ao-Ieong G, Brameld KA, Chin E, de Vicente J, Dunn JP, Ghate M, Giannetti AM, Harris SF, Labadie SS, Leveque V, Li J, Lui AS, McCaleb KL, Najera I, Schoenfeld RC, Wang B, Wong A, J Med Chem. 2013 Apr 11;56(7):3115-9. doi: 10.1021/jm4002605. Epub 2013 Mar 29. PMID:23509929 | ||||||||||||||
| Data retrieval |
![]() |
| View 4IH5 in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |